Type 2 diabetes enhances arterial uptake of choline in atherosclerotic mice: an imaging study with positron emission tomography tracer 18F-fluoromethylcholine
Tóm tắt
Diabetes is a risk factor for atherosclerosis associated with oxidative stress, inflammation and cell proliferation. The purpose of this study was to evaluate arterial choline uptake and its relationship to atherosclerotic inflammation in diabetic and non-diabetic hypercholesterolemic mice. Low-density lipoprotein-receptor deficient mice expressing only apolipoprotein B100, with or without type 2 diabetes caused by pancreatic overexpression of insulin-like growth factor II (IGF-II/LDLR−/−ApoB100/100 and LDLR−/−ApoB100/100) were studied. Distribution kinetics of choline analogue 18F-fluoromethylcholine (18F-FMCH) was assessed in vivo by positron emission tomography (PET) imaging. Then, aortic uptakes of 18F-FMCH and glucose analogue 18F-fluorodeoxyglucose (18F-FDG), were assessed ex vivo by gamma counting and autoradiography of tissue sections. The 18F-FMCH uptake in atherosclerotic plaques was further compared with macrophage infiltration and the plasma levels of cytokines and metabolic markers. The aortas of all hypercholesterolemic mice showed large, macrophage-rich atherosclerotic plaques. The plaque burden and densities of macrophage subtypes were similar in diabetic and non-diabetic animals. The blood clearance of 18F-FMCH was rapid. Both the absolute 18F-FMCH uptake in the aorta and the aorta-to-blood uptake ratio were higher in diabetic than in non-diabetic mice. In autoradiography, the highest 18F-FMCH uptake co-localized with macrophage-rich atherosclerotic plaques. 18F-FMCH uptake in plaques correlated with levels of total cholesterol, insulin, C-peptide and leptin. In comparison with 18F-FDG, 18F-FMCH provided similar or higher plaque-to-background ratios in diabetic mice. Type 2 diabetes enhances the uptake of choline that reflects inflammation in atherosclerotic plaques in mice. PET tracer 18F-FMCH is a potential tool to study vascular inflammation associated with diabetes.
Tài liệu tham khảo
Seshasai SRK, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.
Pasterkamp G. Methods of accelerated atherosclerosis in diabetic patients. Heart. 2013;99:743–9.
Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–8.
Rudd JHF, Narula J, Strauss HW, Virmani R, Machac J, Klimas M, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography. Ready for prime time? J Am Coll Cardiol. 2010;55:2527–35.
Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell. 2011;145:341–55.
Kim TN, Kim S, Yang SJ, Yoo HJ, Seo JA, Kim SG, et al. Vascular inflammation in patients with impaired glucose tolerance and type 2 diabetes: analysis with 18F-fluorodeoxyglucose positron emission tomography. Circ Cardiovasc Imaging. 2010;3:142–8.
Bucerius J, Mani V, Moncrieff C, Rudd JHF, MacHac J, Fuster V, et al. Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol. 2012;59:2080–8.
Tahara N, Kai H, Yamagishi S, Mizoguchi M, Nakaura H, Ishibashi M, et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 2007;49:1533–9.
Kang S, Kyung C, Park JS, Kim S, Lee S-P, Kim MK, et al. Subclinical vascular inflammation in subjects with normal weight obesity and its association with body fat: an 18F-FDG-PET/CT study. Cardiovasc Diabetol. 2014;13:70.
Rudd JHF, Warburton EA, Fryer TD, Jones HA, Clark JC, Antoun N, et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation. 2002;105:2708–11.
Ogawa M, Nakamura S, Saito Y, Kosugi M, Magata Y. What can be seen by 18F-FDG PET in atherosclerosis imaging? The effect of foam cell formation on 18F-FDG uptake to macrophages in vitro. J Nucl Med. 2012;53:55–8.
Tawakol A, Singh P, Mojena M, Pimentel-Santillana M, Emami H, MacNabb M, et al. HIF-1 and PFKFB3 mediate a tight relationship between proinflammatory activation and anerobic metabolism in atherosclerotic macrophages. Arterioscler Thromb Vasc Biol. 2015;35:1463–71.
Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages: implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-d-glucose positron emission tomography. J Am Coll Cardiol. 2011;58:603–14.
Pedersen SF, Græbe M, Hag AMF, Højgaard L, Sillesen H. 18F-FDG imaging of human atherosclerotic carotid plaques reflects gene expression of the key hypoxia marker HIF-1α. Am J Nucl Med Mol Imaging. 2013;3:384–92.
Tekabe Y, Luma J, Einstein AJ, Sedlar M, Li Q, Schmidt AM, et al. A novel monoclonal antibody for RAGE-directed imaging identifies accelerated atherosclerosis in diabetes. J Nucl Med. 2010;51:92–7.
Rominger A, Saam T, Vogl E, Ubleis C, la Fougère C, Förster S, et al. In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: correlation with coronary calcium burden and risk factors. J Nucl Med. 2010;51:193–7.
Gaemperli O, Shalhoub J, Owen DRJ, Lamare F, Johansson S, Fouladi N, et al. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. Eur Heart J. 2012;33:1902–10.
Treglia G, Giovannini E, Di Franco D, Calcagni ML, Rufini V, Picchio M, et al. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review. Ann Nucl Med. 2012;26:451–61.
Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates. Urol Oncol Semin Orig Investig. 2013;31:427–35.
Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Möttönen T, et al. Use of positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-d-glucose in comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of synovium. Arthritis Rheum. 2003;48:3077–84.
Wyss MT, Weber B, Honer M, Späth N, Ametamey SM, Westera G, et al. 18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET. Eur J Nucl Med Mol Imaging. 2004;31:312–6.
Laitinen IEK, Luoto P, Någren K, Marjamäki PM, Silvola JMU, Hellberg S, et al. Uptake of 11C-choline in mouse atherosclerotic plaques. J Nucl Med. 2010;51:798–802.
Matter CM, Wyss MT, Meier P, Späth N, Von Lukowicz T, Lohmann C, et al. 18F-choline images murine atherosclerotic plaques ex vivo. Arterioscler Thromb Vasc Biol. 2006;26:584–9.
Sarda-Mantel L, Alsac JM, Boisgard R, Hervatin F, Montravers F, Tavitian B, et al. Comparison of 18F-fluoro-deoxy-glucose, 18F-fluoro-methyl-choline, and 18F-DPA714 for positron-emission tomography imaging of leukocyte accumulation in the aortic wall of experimental abdominal aneurysms. J Vasc Surg. 2012;56:765–73.
Kato K, Schober O, Ikeda M, Schäfers M, Ishigaki T, Kies P, et al. Evaluation and comparison of 11C-choline uptake and calcification in aortic and common carotid arterial walls with combined PET/CT. Eur J Nucl Med Mol Imaging. 2009;36:1622–8.
Bucerius J, Schmaljohann J, Böhm I, Palmedo H, Guhlke S, Tiemann K, et al. Feasibility of 18F-fluoromethylcholine PET/CT for imaging of vessel wall alterations in humans-First results. Eur J Nucl Med Mol Imaging. 2008;35:815–20.
Heinonen SE, Leppänen P, Kholová I, Lumivuori H, Häkkinen SK, Bosch F, et al. Increased atherosclerotic lesion calcification in a novel mouse model combining insulin resistance, hyperglycemia, and hypercholesterolemia. Circ Res. 2007;101:1058–67.
Véniant MM, Zlot CH, Walzem RL, Pierotti V, Driscoll R, Dichek D, et al. Lipoprotein clearance mechanisms in LDL receptor-deficient “apo-B48- only” and “apo-B100-only” mice. J Clin Invest. 1998;102:1559–68.
Kolthammer JA, Corn DJ, Tenley N, Wu C, Tian H, Wang Y, et al. PET imaging of hepatocellular carcinoma with 18F-fluoroethylcholine and 11C-choline. Eur J Nucl Med Mol Imaging. 2011;38:1248–56.
Silvola JMU, Saraste A, Laitinen I, Savisto N, Laine VJO, Heinonen SE, et al. Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC Cardiovasc Imaging. 2011;4:1294–301.
Haukkala J, Laitinen I, Luoto P, Iveson P, Wilson I, Karlsen H, et al. 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur J Nucl Med Mol Imaging. 2009;36:2058–67.
Rinne P, Silvola JMU, Hellberg S, Ståhle M, Liljenbäck H, Salomäki H, et al. Pharmacological activation of the melanocortin system limits plaque inflammation and ameliorates vascular dysfunction in atherosclerotic mice. Arterioscler Thromb Vasc Biol. 2014;34:1346–54.
Hong HC, Hwang SY, Park S, Ryu JY, Choi HY, Yoo HJ, et al. Implications of pericardial, visceral and subcutaneous adipose tissue on vascular Inflammation measured using 18FDG-PET/CT. PLoS One. 2015;10:e0135294.
Heinonen SE, Merentie M, Hedman M, Mäkinen PI, Loponen E, Kholová I, et al. Left ventricular dysfunction with reduced functional cardiac reserve in diabetic and non-diabetic LDL-receptor deficient apolipoprotein B100-only mice. Cardiovasc Diabetol. 2011;10:59.
De Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BHR, Van Tol A, Dullaart RPF. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia. 2006;49:398–404.
Zhang K, Liu X, Yu Y, Luo T, Wang L, Ge C, et al. Phospholipid transfer protein destabilizes mouse atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2014;34:2537–44.
Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA. 1986;256:2823–8.
Schuett H, Oestreich R, Waetzig GH, Annema W, Luchtefeld M, Hillmer A, et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2012;32:281–90.
Koh KK, Park SM, Quon MJ. Leptin and cardiovascular disease: response to therapeutic interventions. Circulation. 2008;117:3238–49.
Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980;19:205–10.
Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–72.
Veillard NR, Kwak B, Pelli G, Mulhaupt F, James RW, Proudfoot A, et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ Res. 2004;94:253–61.
Kim DS, Burt AA, Ranchalis JE, Vuletic S, Vaisar T, Li W-F, et al. Plasma phospholipid transfer protein (PLTP) activity inversely correlates with carotid artery disease: effects of paraoxonase 1 enzyme activity and genetic variants on PLTP activity. J Lipid Res. 2015;56:1351–62.
Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473–80.
Tward A, Xia Y-R, Wang X-P, Shi Y-S, Park C, Castellani LW, et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation. 2002;106:484–90.
Buettner C, Rudd JHF, Fayad ZA. Determinants of FDG uptake in atherosclerosis. JACC Cardiovasc Imaging. 2011;4:1302–4.